Status:
RECRUITING
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Hyperfibrinogenemia
Hemostatic Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Few reliable data are available on these changes and most studies are limited to coagula...
Detailed Description
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Some data are available on changes in circulating haemostasis factors with the Single Pl...
Eligibility Criteria
Inclusion
- Patients without renal failure treated with chronic therapeutic plasmapheresis with a minimum treatment interval of 10 days and who can be treated with single plasma exchange (SPE) or double filtration plasmapheresis (DFPP) in accordance with the international recommendations.
- Therapeutic plasmapheresis with regional citrate anticoagulation.
- Patients over 18 years of age.
- Patient affiliated to or benefiting from a social security scheme.
- Free, informed and written consent, signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion
- Patients treated with oral anticoagulants or anti-platelet agents.
- Patients treated for hypercholesterolaemia or hypertriglyceridaemia; hyperviscosity, acquired haemophilia or nephrotic syndrome.
- Indication for substitution with fresh frozen plasma (FFP) for the treatment of the disease.
- Patient in an exclusion period determined by another study.
- Patient under court protection, guardianship or curatorship.
- Patient unable to give consent.
- Patient for whom it is impossible to give informed information.
- Pregnant or breast-feeding patients.
Key Trial Info
Start Date :
December 17 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06571552
Start Date
December 17 2024
End Date
June 1 2026
Last Update
December 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nîmes
Nîmes, France, 30029